ThinkstockCreating the most popular product of the year will make consumers and investors happy. But making an all-time bestseller can transform an industry and define a business for decades. Many of the…
thinkstockMay 6, 2014: Markets opened lower on Monday and sank slowly and surely for the rest of the day. The dollar weakened against the yen overnight removing some enthusiasm for risk in…
Merck has had its consumer products business on the market since the beginning of this year, and Tuesday it announced that it had sold the business to Germany-based Bayer for $14.2 billion.
thinkstockMay 5, 2014: Markets opened lower on Monday but gamely pushed to the upside in midafternoon. General concern over the situation in Ukraine and a weaker outlook on global growth prospects kept…
Drug giant Pfizer reported better-than-expected first-quarter 2014 earnings before markets opened Monday morning, but revenues fell short. Shares traded lower in the premarket.
Jon OggEarnings season is far from over, but roughly three quarters of the stocks in the Standard & Poor’s 500 Index stocks have now reported their earnings for the first calendar quarter of…
British drug maker AstraZeneca once again rejected a takeover bid from U.S. pharmaceutical giant Pfizer, this one worth $106 billion (about £50 a share) in cash and stock.
thinkstockApril 28, 2014: Markets opened higher on Monday with little economic data to drive the market either up or down. Consequently shares fell then rose and look to be headed for small…
The NYSE Arca Biotechnology Index fell nearly 9% between a peak on Jan. 22 and a low on Feb. 5. It jumped 23% over the next three weeks, and then gave it…
In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are making major advances in cancer therapeutics. Here is the UBS list of…
thinkstockApril 21 2014: Markets opened higher on Monday but there wasn’t a lot of action as the only data out today was leading indicators, and they came in right on estimates. At…
Paul Ausick ThinkstockIt is not that common that you hear about mergers in the $50 billion range. But what about when you hear of mergers in the $80 billion or $100 billion range? AstraZeneca…
Canaccord Genuity is one of the few firms that are willing to cover small-cap biotech and emerging pharma stocks. Sometimes the price target upside is off the charts as well. In case…
Jon C. Ogg thinkstockApril 7, 2014: Markets opened lower on Monday and were on a downhill slide all day long. Momentum stocks again had a terrible day. At the close of trading today the DJIA…
While the FDA has been far from a friend to MannKind over the past few years, the latest FDA panel backing may have given diabetes patients and investors some hope. That hope…
